Bio-Rad Laboratories, Inc. (USD) Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Bio-Rad Laboratories, Inc. (USD) Active

1000 Alfred Nobel Drive, Hercules, CA, US, 94547

Stock Price USD

Price Change

Last Dividend USD

C+

Latest Rating

BIO's stock peer is ANIK (Anika Therapeutics, Inc.)

BIO's stock peer is BRKR (Bruker Corporation)

BIO's stock peer is CNMD (CONMED Corporation)

BIO's stock peer is GKOS (Glaukos Corporation)

BIO's stock peer is GMED (Globus Medical, Inc.)

BIO's stock peer is INSP (Inspire Medical Systems, Inc.)

BIO's stock peer is ITGR (Integer Holdings Corporation)

BIO's stock peer is NARI (Inari Medical, Inc.)

BIO's stock peer is NVCR (NovoCure Limited)

BIO's stock peer is PEN (Penumbra, Inc.)

BIO's stock peer is PODD (Insulet Corporation)

BIO's stock peer is SWAV (ShockWave Medical, Inc.)

BIO's stock peer is TNDM (Tandem Diabetes Care, Inc.)

BIO's stock peer is ZBH (Zimmer Biomet Holdings, Inc.)

Healthcare Medical - Devices

Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

60%

Dcf Rating

20%

Return On Equity

20%

Return On Assets

40%

Debt To Equity

20%

Price To Earnings

80%

Price To Book

Income Statement

Dividend Stats Yield is calculated via trailing-12-month period

Ex-Dividend	Payment Date	Dividend	Yield	Dividend Frequency
Dividend Data Not Exist

Recent News

Telomir Pharmaceuticals to Participate in BIO 2025 in Boston as Company Prepares for IND Submission and Advances Breakthrough Longevity Platform

Company to meet with prospective partners as it accelerates toward IND submission for Telomir-1, with plans to begin human dosing in the first half of 2026 MIAMI, FL / ACCESS Newswire / June 2, 2025 / Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) ("Telomir" or the "Company"), an emerging leader in age-reversal science, today announced its participation in the BIO International Convention 2025, taking place in Boston, MA from June 16-19, 2025. The Company has scheduled a full week of BIO One-on-One Partnering™ meetings to explore strategic collaborations, licensing opportunities, and potential M&A transactions.

2025-06-02 08:30:00

VERAXA Biotech to Attend Key Industry Conferences to Showcase BiTAC Technology Platform

VERAXA Attending ASCO and BIO with Cantor Fitzgerald, Voyager's Recently Retained Capital Markets Advisor, and Hosting Meetings with Potential Partners and Investors VERAXA Attending ASCO and BIO with Cantor Fitzgerald, Voyager's Recently Retained Capital Markets Advisor, and Hosting Meetings with Potential Partners and Investors

2025-05-29 18:34:00

Bio-Rad's Management to Host Investor Meetings During Jefferies Global Healthcare Conference

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company's Chief Operating Officer Jon DiVincenzo will host one-on-one meetings with investors during the Jefferies Global Healthcare Conference in New York City, on June 4, 2025. About Bio-Rad Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range o.

2025-05-29 16:30:00

VERAXA Biotech to Attend Key Industry Conferences to Showcase BiTAC Technology Platform

2025-05-29 10:34:00

Biometric Identity and Access Management Software Solutions Provider BIO-key Announces Two Webcast Investor Presentations: Aegis Capital Thu. May 22 at 11:30am ET and Maxim Group Wed.

HOLMDEL, N.J., May 20, 2025 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (Nasdaq: BKYI), an innovative provider of workforce and customer Identity and Access Management (IAM) solutions featuring passwordless, phoneless and tokenless, Identity-Bound Biometric (IBB) authentication solutions today announces its participation at the Aegis Capital Corp. 2025 Virtual Conference on Thursday, May 22nd and the Maxim Virtual Tech Conference on Wednesday, June 4th – webcast access details provided below.

2025-05-20 07:59:00

BIO-key and Cloud Distribution Co. Partner to Expand IAM and Biometric Security Solutions Across the Middle East

BIO-key & Cloud Distribution Partner to Expand Advanced Identity Access Management & Biometric Security Solutions Across Middle East via Saudi-based VAR.

2025-05-19 07:59:00

BIO-key Reports Q1'25 Revenue of $1.6M and Improved Cash Position of $3.1M; Hosts Investor Call Tomorrow, Friday May 16th at 10am ET

HOLMDEL, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- BIO-key ® International, Inc. (Nasdaq: BKYI), an innovative provider of workforce and customer Identity and Access Management (IAM) solutions featuring passwordless, phoneless and tokenless Identity-Bound Biometric (IBB) authentication, announced results for its first quarter (Q1'25).

2025-05-15 16:15:00

Bio-Rad's Management to Participate in Fireside Chat During 2025 RBC Capital Markets Global Healthcare Conference

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Executive Officer Norman Schwartz and Chief Financial Officer Roop K. Lakkaraju will participate in a fireside chat event during the 2025 RBC Capital Markets Global Healthcare Conference on Wednesday, May 21, 2025, at 1:35 PM Eastern Time (10:35 AM Pacific Time). A live webcast and subsequent replay of the.

2025-05-12 16:30:00

BIO-key, Provider of Identity and Access Management Solutions Enhanced with Biometric Authentication Hosts Q1 Investor Call Fri. May 16th at 10am ET

BKYI: BIO-key, Provider of Identity and Access Management Solutions Enhanced with Biometric Authentication Hosts Q1 Investor Call Fri. May 16th at 10am ET.

2025-05-09 11:00:00

BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2025 RESULTS

MINNEAPOLIS , May 7, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the third quarter ending March 31, 2025. Third Quarter FY2025 Highlights Third quarter organic revenue increased by 6% (4% reported) to $316.2 million.

2025-05-07 06:30:00

Disclaimers

StockQuay.com is not operated by a broker, dealer, or registered investment advisor. Under no circumstances should any information published on StockQuay.com be considered a recommendation to buy, sell, or hold any security. The content on this site and in its associated newsletters is intended solely for informational and educational purposes and does not constitute investment advice or financial recommendations.

Individuals or entities featured or referenced on StockQuay.com may engage in trading activity involving the securities mentioned in any article or report before or after such content is published. These individuals or entities are not affiliated with StockQuay.com, and their inclusion does not imply endorsement or accuracy of their views or actions.

StockQuay.com, its owners, or its affiliates shall not be held liable to any user or third party for any damages or losses arising from the use of content on this website. This includes, but is not limited to, investment losses, loss of profit, loss of data, missed opportunities, or indirect, incidental, or consequential damages.

Data is updated daily and is not guaranteed to be accurate or complete.

Past performance is not indicative of future results. Please conduct your own research or consult with a qualified financial advisor before making any investment decisions